The ARF tumor suppressor targets PPM1G/PP2Cγ to counteract NF-κB transcription tuning cell survival and the inflammatory response.
Apoptosis
/ drug effects
Cell Survival
/ drug effects
Epithelial Cells
/ pathology
Humans
Inflammation
/ genetics
Multiprotein Complexes
NF-kappa B
/ genetics
Neoplasms
/ genetics
Promoter Regions, Genetic
Protein Domains
Protein Interaction Maps
Protein Phosphatase 2C
/ chemistry
Transcription, Genetic
Tumor Necrosis Factor-alpha
/ pharmacology
Tumor Suppressor Protein p14ARF
/ genetics
ARF
NF-κB
PPM1G
gene regulation
inflammatory response
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
22 12 2020
22 12 2020
Historique:
pubmed:
9
12
2020
medline:
20
2
2021
entrez:
8
12
2020
Statut:
ppublish
Résumé
Inducible transcriptional programs mediate the regulation of key biological processes and organismal functions. Despite their complexity, cells have evolved mechanisms to precisely control gene programs in response to environmental cues to regulate cell fate and maintain normal homeostasis. Upon stimulation with proinflammatory cytokines such as tumor necrosis factor-α (TNF), the master transcriptional regulator nuclear factor (NF)-κB utilizes the PPM1G/PP2Cγ phosphatase as a coactivator to normally induce inflammatory and cell survival programs. However, how PPM1G activity is precisely regulated to control NF-κB transcription magnitude and kinetics remains unknown. Here, we describe a mechanism by which the ARF tumor suppressor binds PPM1G to negatively regulate its coactivator function in the NF-κB circuit thereby promoting insult resolution. ARF becomes stabilized upon binding to PPM1G and forms a ternary protein complex with PPM1G and NF-κB at target gene promoters in a stimuli-dependent manner to provide tunable control of the NF-κB transcriptional program. Consistently, loss of ARF in colon epithelial cells leads to up-regulation of NF-κB antiapoptotic genes upon TNF stimulation and renders cells partially resistant to TNF-induced apoptosis in the presence of agents blocking the antiapoptotic program. Notably, patient tumor data analysis validates these findings by revealing that loss of
Identifiants
pubmed: 33288725
pii: 2004470117
doi: 10.1073/pnas.2004470117
pmc: PMC7768782
doi:
Substances chimiques
Multiprotein Complexes
0
NF-kappa B
0
Tumor Necrosis Factor-alpha
0
Tumor Suppressor Protein p14ARF
0
PPM1G protein, human
EC 3.1.3.16
Protein Phosphatase 2C
EC 3.1.3.16
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32594-32605Subventions
Organisme : NCI NIH HHS
ID : P30 CA142543
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007062
Pays : United States
Déclaration de conflit d'intérêts
The authors declare no competing interest.
Références
Nature. 2019 Apr;568(7751):249-253
pubmed: 30894749
Nat Rev Mol Cell Biol. 2015 Jul;16(7):393-405
pubmed: 26122615
EMBO J. 1998 Sep 1;17(17):5001-14
pubmed: 9724636
Cell. 2007 Nov 16;131(4):669-81
pubmed: 18022362
Oncoimmunology. 2012 Sep 1;1(6):946-947
pubmed: 23162766
Biochim Biophys Acta. 2013 Sep;1829(9):937-45
pubmed: 23624258
Genes Dev. 2004 Aug 1;18(15):1862-74
pubmed: 15289458
Nat Rev Genet. 2012 Oct;13(10):720-31
pubmed: 22986266
Cold Spring Harb Perspect Biol. 2009 Oct;1(4):a000034
pubmed: 20066092
J Cell Biol. 2006 Nov 6;175(3):389-400
pubmed: 17074886
Science. 1996 Nov 1;274(5288):782-4
pubmed: 8864118
EMBO J. 2006 Sep 20;25(18):4284-92
pubmed: 16957780
Crit Rev Biochem Mol Biol. 2007 Nov-Dec;42(6):437-61
pubmed: 18066953
Cancer Res. 1999 May 1;59(9):2217-22
pubmed: 10232611
Cell. 2009 Jul 10;138(1):129-45
pubmed: 19596240
Nucleic Acids Res. 2011 Nov;39(21):9167-80
pubmed: 21846774
Gastroenterology. 2010 Mar;138(3):1012-21.e1-5
pubmed: 19962984
Cell. 2000 Oct 13;103(2):263-71
pubmed: 11057899
Nat Rev Cancer. 2012 Jan 19;12(2):121-32
pubmed: 22257950
Science. 2008 Mar 28;319(5871):1791-2
pubmed: 18369138
Nat Immunol. 2011 Jul 19;12(8):689-94
pubmed: 21772277
Oncogene. 2006 Oct 30;25(51):6831-43
pubmed: 17072331
Transcription. 2019 Apr;10(2):57-75
pubmed: 30227759
Mol Cell. 2013 Apr 25;50(2):212-22
pubmed: 23523369
Int J Cancer. 2010 Nov 15;127(10):2239-47
pubmed: 20549699
Oncogene. 2002 Jul 4;21(29):4498-507
pubmed: 12085228
Science. 1996 Nov 1;274(5288):724
pubmed: 8966553
Nature. 1999 Apr 29;398(6730):828-32
pubmed: 10235267
RNA Dis. 2016;3(1):
pubmed: 27088130
Nat Struct Mol Biol. 2010 Jul;17(7):815-21
pubmed: 20562857
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
Mol Cell. 2006 Aug 4;23(3):297-305
pubmed: 16885020
Genes Dev. 2013 May 15;27(10):1079-88
pubmed: 23699407
Cell Cycle. 2005 Jun;4(6):756-9
pubmed: 15970704
Cell. 2007 Nov 16;131(4):655-8
pubmed: 18022360
Science. 1996 Nov 1;274(5288):784-7
pubmed: 8864119
Cell Rep. 2013 Dec 12;5(5):1256-68
pubmed: 24316072
Nat Rev Cancer. 2002 Apr;2(4):301-10
pubmed: 12001991
Cell. 2010 Mar 19;140(6):833-44
pubmed: 20303874
Science. 1996 Aug 9;273(5276):735-7
pubmed: 8701321
J Biol Chem. 2014 Dec 12;289(50):34921-37
pubmed: 25331947
Cells. 2016 Mar 18;5(1):
pubmed: 26999213
Annu Rev Immunol. 1998;16:225-60
pubmed: 9597130
Mol Cell. 2003 Jul;12(1):15-25
pubmed: 12887889
Cell. 2015 Feb 26;160(5):816-827
pubmed: 25723161
Mediators Inflamm. 2012;2012:568783
pubmed: 23316105
Science. 1996 Nov 1;274(5288):787-9
pubmed: 8864120
J Immunol. 2011 Dec 15;187(12):6527-38
pubmed: 22095712
Oncogene. 2014 Jan 16;33(3):300-7
pubmed: 23318441
Annu Rev Biochem. 2012;81:119-43
pubmed: 22404626
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):2927-32
pubmed: 9096323
Cancer Cell. 2007 Nov;12(5):445-56
pubmed: 17996648
Oncoimmunology. 2012 Nov 1;1(8):1227-1238
pubmed: 23243586
Cell. 2008 Feb 8;132(3):344-62
pubmed: 18267068
Mol Cell Biol. 2015 Nov;35(22):3810-28
pubmed: 26324325
J Vis Exp. 2017 Jan 26;(119):
pubmed: 28190026
Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a000109
pubmed: 20516126
Cell. 1995 Dec 15;83(6):993-1000
pubmed: 8521522